In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity

The aim of this study was to evaluate the effect of olmesartan (OLME), an angiotensin II receptor antagonist, on an intestinal mucositis model. Briefly, daily intraperitoneal (i.p.) injections of methotrexate (MTX) 7 mg/kg were administered to rats on 3 consecutive days. A subset of these rats was a...

ver descrição completa

Na minha lista:

Detalhes bibliográficos
Principais autores:	Araújo, Aurigena Antunes de, Borba, Pedro Brito, Souza, Fernando Henrique Destefani de, Nogueira, Anália Cristina, Saldanha, Taís Suassuna, Araújo, Thayse Emanuele Franklin, Silva, Aldemara Ingrid da, Araújo Júnior, Raimundo Fernandes de
Formato:	article
Idioma:	eng
Publicado em:	The Pharmaceutical Society of Japan
Assuntos:	intestinal mucositis model olmesartan inflammation
Endereço do item:	https://repositorio.ufrn.br/jspui/handle/123456789/25429 https://doi.org/10.1248/bpb.b14-00847
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

id	ri-123456789-25429
record_format	dspace
spelling	ri-123456789-254292021-11-11T19:16:45Z In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity Araújo, Aurigena Antunes de Borba, Pedro Brito Souza, Fernando Henrique Destefani de Nogueira, Anália Cristina Saldanha, Taís Suassuna Araújo, Thayse Emanuele Franklin Silva, Aldemara Ingrid da Araújo Júnior, Raimundo Fernandes de intestinal mucositis model olmesartan inflammation The aim of this study was to evaluate the effect of olmesartan (OLME), an angiotensin II receptor antagonist, on an intestinal mucositis model. Briefly, daily intraperitoneal (i.p.) injections of methotrexate (MTX) 7 mg/kg were administered to rats on 3 consecutive days. A subset of these rats was also pretreated with oral administration of OLME (0.5, 1.0, or 5.0 mg/kg) or vehicle as a control 30 min prior to MTX injection. Body weight, feces scoring, and death were recorded daily. On day 4, the rats were killed, and intestinal tissues were assayed for levels of interleukin (IL)-1β and tumor necrosis factor (TNF)-α, myeloperoxidase and sucrose activity, and histopathological findings. A significant reduction in body weight was observed in the MTX+1.0 mg/kg OLME group (p<0.01). The feces scores for the MTX+0.5 mg/kg OLME and MTX+5.0 mg/kg OLME groups were also significantly higher (p<0.001). Sucrose activity was reduced in all groups treated with OLME (p<0.05). Treatment with MTX+OLM at all doses resulted in reduced inflammatory infiltration, ulcerations, vasodilation, and hemorrhagic areas (p<0.05), as well as reduced concentrations of myeloperoxidase (p<0.001). The IL-1β and TNF-α levels were decreased in the MTX+OLME 5.0 mg/kg (p<0.01 and p<0.05, respectively) compared with the MTX-alone group. Overall, antiinflammatory activity was observed in rats with MTX-induced intestinal mucositis that were administered OLME. However, further studies are needed to elucidate the adverse effects of OLME. 2018-06-16T12:36:20Z 2018-06-16T12:36:20Z 2015 article ARAÚJO, Aurigena Antunes de et al. In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity. Biological & Pharmaceutical Bulletin, v. 38, p. 746-752, 2015. Disponível em: <https://www.jstage.jst.go.jp/article/bpb/38/5/38_b14-00847/_article>. Acesso em: 20 mar. 2018. 1347-5215 https://repositorio.ufrn.br/jspui/handle/123456789/25429 https://doi.org/10.1248/bpb.b14-00847 eng Acesso Aberto application/pdf The Pharmaceutical Society of Japan
institution	Repositório Institucional
collection	RI - UFRN
language	eng
topic	intestinal mucositis model olmesartan inflammation
spellingShingle	intestinal mucositis model olmesartan inflammation Araújo, Aurigena Antunes de Borba, Pedro Brito Souza, Fernando Henrique Destefani de Nogueira, Anália Cristina Saldanha, Taís Suassuna Araújo, Thayse Emanuele Franklin Silva, Aldemara Ingrid da Araújo Júnior, Raimundo Fernandes de In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
description	The aim of this study was to evaluate the effect of olmesartan (OLME), an angiotensin II receptor antagonist, on an intestinal mucositis model. Briefly, daily intraperitoneal (i.p.) injections of methotrexate (MTX) 7 mg/kg were administered to rats on 3 consecutive days. A subset of these rats was also pretreated with oral administration of OLME (0.5, 1.0, or 5.0 mg/kg) or vehicle as a control 30 min prior to MTX injection. Body weight, feces scoring, and death were recorded daily. On day 4, the rats were killed, and intestinal tissues were assayed for levels of interleukin (IL)-1β and tumor necrosis factor (TNF)-α, myeloperoxidase and sucrose activity, and histopathological findings. A significant reduction in body weight was observed in the MTX+1.0 mg/kg OLME group (p<0.01). The feces scores for the MTX+0.5 mg/kg OLME and MTX+5.0 mg/kg OLME groups were also significantly higher (p<0.001). Sucrose activity was reduced in all groups treated with OLME (p<0.05). Treatment with MTX+OLM at all doses resulted in reduced inflammatory infiltration, ulcerations, vasodilation, and hemorrhagic areas (p<0.05), as well as reduced concentrations of myeloperoxidase (p<0.001). The IL-1β and TNF-α levels were decreased in the MTX+OLME 5.0 mg/kg (p<0.01 and p<0.05, respectively) compared with the MTX-alone group. Overall, antiinflammatory activity was observed in rats with MTX-induced intestinal mucositis that were administered OLME. However, further studies are needed to elucidate the adverse effects of OLME.
format	article
author	Araújo, Aurigena Antunes de Borba, Pedro Brito Souza, Fernando Henrique Destefani de Nogueira, Anália Cristina Saldanha, Taís Suassuna Araújo, Thayse Emanuele Franklin Silva, Aldemara Ingrid da Araújo Júnior, Raimundo Fernandes de
author_facet	Araújo, Aurigena Antunes de Borba, Pedro Brito Souza, Fernando Henrique Destefani de Nogueira, Anália Cristina Saldanha, Taís Suassuna Araújo, Thayse Emanuele Franklin Silva, Aldemara Ingrid da Araújo Júnior, Raimundo Fernandes de
author_sort	Araújo, Aurigena Antunes de
title	In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
title_short	In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
title_full	In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
title_fullStr	In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
title_full_unstemmed	In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity
title_sort	in a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation and induced enteropathy characterized by severe diarrhea, weight loss, and reduced sucrose activity
publisher	The Pharmaceutical Society of Japan
publishDate	2018
url	https://repositorio.ufrn.br/jspui/handle/123456789/25429 https://doi.org/10.1248/bpb.b14-00847
work_keys_str_mv	AT araujoaurigenaantunesde inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT borbapedrobrito inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT souzafernandohenriquedestefanide inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT nogueiraanaliacristina inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT saldanhataissuassuna inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT araujothayseemanuelefranklin inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT silvaaldemaraingridda inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity AT araujojuniorraimundofernandesde inamethotrexateinducedmodelofintestinalmucositisolmesartanreducedinflammationandinducedenteropathycharacterizedbyseverediarrheaweightlossandreducedsucroseactivity
_version_	1773966364294250496

In a Methotrexate-Induced Model of Intestinal Mucositis, Olmesartan Reduced Inflammation and Induced Enteropathy Characterized by Severe Diarrhea, Weight Loss, and Reduced Sucrose Activity

Registros relacionados